ATE354662T1 - Modifizierte hpv e6- und e7-gene und -proteine als impfstoff - Google Patents

Modifizierte hpv e6- und e7-gene und -proteine als impfstoff

Info

Publication number
ATE354662T1
ATE354662T1 AT01107271T AT01107271T ATE354662T1 AT E354662 T1 ATE354662 T1 AT E354662T1 AT 01107271 T AT01107271 T AT 01107271T AT 01107271 T AT01107271 T AT 01107271T AT E354662 T1 ATE354662 T1 AT E354662T1
Authority
AT
Austria
Prior art keywords
dna sequences
protein
vaccine
genes
proteins
Prior art date
Application number
AT01107271T
Other languages
English (en)
Inventor
Angel Dr Cid-Arregui
Hausen Harald Prof Dr Zur
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of ATE354662T1 publication Critical patent/ATE354662T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT01107271T 2001-03-23 2001-03-23 Modifizierte hpv e6- und e7-gene und -proteine als impfstoff ATE354662T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20010107271 EP1243655B1 (de) 2001-03-23 2001-03-23 Modifizierte HPV E6- und E7-Gene und -Proteine als Impfstoff

Publications (1)

Publication Number Publication Date
ATE354662T1 true ATE354662T1 (de) 2007-03-15

Family

ID=8176911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01107271T ATE354662T1 (de) 2001-03-23 2001-03-23 Modifizierte hpv e6- und e7-gene und -proteine als impfstoff

Country Status (9)

Country Link
US (3) US7201908B2 (de)
EP (1) EP1243655B1 (de)
JP (1) JP2004531253A (de)
AT (1) ATE354662T1 (de)
AU (1) AU2002312774A1 (de)
DE (1) DE60126737T2 (de)
ES (1) ES2284559T3 (de)
MX (1) MXPA03008559A (de)
WO (1) WO2002081709A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284559T3 (es) * 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.
AU2003221650A1 (en) * 2002-04-24 2003-11-10 Universite Libre De Bruxelles Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process
CZ297389B6 (cs) * 2003-07-03 2006-11-15 Ústav Molekulární Biologie Rostlin Av Cr Fúzní protein pro vakcinaci proti lidskému papillomaviru a zpusob jeho produkce
JPWO2005049824A1 (ja) * 2003-11-21 2007-11-29 独立行政法人科学技術振興機構 生体構造認識部位を提示する中空ナノ粒子およびその生産方法、並びにその利用
WO2005063286A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
AU2003290460A1 (en) * 2003-12-24 2005-07-14 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
KR100755991B1 (ko) 2005-08-11 2007-09-06 신정임 최적화된 유전자 코돈을 가지는 ｅ7 유전자 및 라이소좀타겟팅 시그널 서열을 포함하는 파필로마바이러스 유발질환의 예방 또는 치료용 조성물
USRE46453E1 (en) * 2006-04-19 2017-06-27 Postech Foundation Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
JP5795319B2 (ja) * 2009-11-06 2015-10-14 チャイメラ ファーマ エス．エル．ユー．Ｃｈｉｍｅｒａ Ｐｈａｒｍａ Ｓ．Ｌ．Ｕ． ヒトパピローマウイルス抗原を含むビルナウイルスのウイルスカプシドに基づく腫瘍形成を処置するためのワクチン
EP2335730A1 (de) * 2009-12-18 2011-06-22 Deutsches Krebsforschungszentrum Fusionspolypeptide und ihre Verwendung zur Vorbeugung und Behandlung von Krebs
PL2604629T3 (pl) 2010-08-13 2018-08-31 Genexine, Inc. Kompozycja do zapobiegania lub leczenia raka szyjki macicy ze wzmacniaczem odporności przeciwko wirusowi brodawczaka ludzkiego
CN103772508B (zh) * 2014-01-15 2017-05-10 深圳泰来生物医药有限公司 免疫增强的人乳头瘤病毒感染及相关疾病的治疗性疫苗
CN107073070A (zh) 2014-08-15 2017-08-18 格纳西尼有限公司 治疗宫颈癌的方法
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗
WO2017096432A1 (en) * 2015-12-09 2017-06-15 Admedus Vaccines Pty Ltd Immunomodulating composition for treatment
CN111019971A (zh) * 2019-12-19 2020-04-17 上海同科生物科技有限公司 在rosa26位点条件性过表达hpv e6基因小鼠模型的构建方法
JP7460094B2 (ja) 2020-04-24 2024-04-02 ジェネクシン・インコーポレイテッド 子宮頸がんの治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882145A (en) * 1986-12-09 1989-11-21 Scripps Clinic And Research Foundation T cell epitopes of the hepatitis B virus nucleocapsid protein
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
DE19819476C1 (de) * 1998-04-30 2000-01-05 Deutsches Krebsforsch Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
EP1212358B1 (de) * 1999-08-25 2004-12-15 Merck & Co., Inc. Synthetische papillomavirus gene, welche für expression in menschlichen zellen optimiert sind
US7001995B1 (en) * 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ES2284559T3 (es) * 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.

Also Published As

Publication number Publication date
MXPA03008559A (es) 2005-03-07
AU2002312774A1 (en) 2002-10-21
WO2002081709A3 (en) 2003-03-06
US20070190074A1 (en) 2007-08-16
US7700114B2 (en) 2010-04-20
DE60126737T2 (de) 2007-11-08
JP2004531253A (ja) 2004-10-14
DE60126737D1 (de) 2007-04-05
ES2284559T3 (es) 2007-11-16
EP1243655A1 (de) 2002-09-25
WO2002081709A2 (en) 2002-10-17
EP1243655B1 (de) 2007-02-21
US20040171806A1 (en) 2004-09-02
US7201908B2 (en) 2007-04-10
US20070196339A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE354662T1 (de) Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
CY1112334T1 (el) Ομολογα πολυπεπτιδια il-17 και θεραπευτικες χρησεις αυτων
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
SI1108035T1 (sl) Zdravljenje raka materničnega vratu
BRPI0409789A (pt) vacina de tuberculose com eficácia aperfeiçoada
MX336112B (es) Vacunas e inmunoterapicos que usan il-15 optimizada de codones y metodos para usar los mismos.
DE60033138D1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
CY1109257T1 (el) Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων
DK1246917T3 (da) Humane Stra6-polypeptider
ATE310810T1 (de) Polypeptid und dafür kodierendes nukeinsäure
ATE325880T1 (de) Herstellung eines rekombinanten proteins in prokaryotischen wirtszellen durch kodonsoptimisierung
DE602005015368D1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
ATE317896T1 (de) Polypeptide mit glucanotransferase aktivität und dafür kodierende nukleinsäuren
SE0002498D0 (sv) Papillomavirus vaccine
DE60038986D1 (de) Ausgeschiedene und Transmembranpolypeptide und dafür kodierende Nukleinsäure
ATE447614T1 (de) Menschliches suppressor von fused
ATE290018T1 (de) Polypeptid und dafür kodieredes nukleinsäure
ATE380864T1 (de) Menschliches prostasin-ähnliches protein und dafür kodierende nukleinsäure
PT1277833E (pt) Gene que e amplificado em tumores e materiais e metodos relacionados
DE69824455D1 (de) PRO241 Polypeptide und dafür kodierende Nukleinsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties